Mersana Therapeutics (MRSN)
(Delayed Data from NSDQ)
$2.57 USD
-0.04 (-1.53%)
Updated May 15, 2024 04:00 PM ET
After-Market: $2.56 -0.01 (-0.39%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
MRSN 2.57 -0.04(-1.53%)
Will MRSN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MRSN based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MRSN
Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates
Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates
MRSN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates
Other News for MRSN
Mersana Therapeutics: On Hold While Waiting For Any Positive News
Truist Financial Sticks to Its Buy Rating for Mersana Therapeutics (MRSN)
Analysts Are Bullish on These Healthcare Stocks: Mersana Therapeutics (MRSN), Insulet (PODD)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Mersana Therapeutics (MRSN), Insulet (PODD) and Crispr Therapeutics AG (CRSP)
Truist Financial Sticks to Their Buy Rating for Mersana Therapeutics (MRSN)